New class of antigen-specific cancer immunotherapy
based on an off-the-shelf antigen presenting cell line

News

Have a look at the interview of our CEO in an on-demand "Fireside Chat"

2020-11

Have a look at the interview of PDC*line Pharma 's CEO Eric Halioua by Andrew McConaghie a journalist of SCRIP in an on-demand "Fireside Chat" session during the BIOEUROPE FALL 2020. He presents the company strategy and how the regional ecosystem has

Read more about Have a look at the interview of our CEO in an on-demand "Fireside Chat"

Our CEO will be today a panelist in a round table on Therapeutic Cancer vaccines and make a company presentation at the Festival of Biologics virtual event

2020-11

Eric Halioua, President & CEO of PDC*line Pharma will be today, Nov. 2nd 2020, a panelist in a round table on Therapeutic Cancer vaccines and make a company presentation at the Festival of Biologics virtual event. A Terrapinn virtual event organized,

Read more about Our CEO will be today a panelist in a round table on Therapeutic Cancer vaccines and make a company presentation at the Festival of Biologics virtual event

PDC*LINE PHARMA TO ATTEND UPCOMING SCIENTIFIC AND PARTNERING CONFERENCES THIS FALL

2020-10

PDC*line Pharma, a biotech company developing a novel class of potent and off-the-shelf cancer immunotherapies to treat cancer patients, today announced that the Company will give presentations and attend to the following scientific and partnering

Read more about PDC*LINE PHARMA TO ATTEND UPCOMING SCIENTIFIC AND PARTNERING CONFERENCES THIS FALL

Dosing of first patient with high dose in ongoing PDC-LUNG-101 clinical trial with our therapeutic cancer vaccine candidate for non-small cell lung cancer

2020-09

Cohorts A2 (single agent high dose in adjuvant setting) and B1 (low dose added to anti-PD-1) have been opened and first patient of cohort A2 has been dosed

Liège, Belgium and Grenoble, France, September 22, 2020 – PDC*line Pharma, a clinical stage

Read more about Dosing of first patient with high dose in ongoing PDC-LUNG-101 clinical trial with our therapeutic cancer vaccine candidate for non-small cell lung cancer

PDC*line Pharma is one of the three nominees for the 2020 BVA Award Venture company of the year!

2020-07

We are very pleased to announce that PDC*line Pharma is one of the three nominees for the 2020 BVA Award Venture company of the year!

THE BELGIAN VENTURE CAPITAL & PRIVATE EQUITY ASSOCIATION AWARD

The Belgian Venture Capital & Private Equity

Read more about PDC*line Pharma is one of the three nominees for the 2020 BVA Award Venture company of the year!

linkedin twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Eric Halioua

Laurent Levy

Dr. Joel Plumas

Claude DEDRY

Dr. Channa Debruyne

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology